A Precision high content screening assay for AB-mediated neuronal cell cycle reentry
A Precision high content screening assay for AB-mediated neuronal cell cycle reentry
批准号:
9904312
负责人:
ELIZABETH SHARLOW
金额:
$40.38万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-01 至 2022-01-31
关键词:
3-DimensionalAffectAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAlzheimer&aposs disease diagnosisAlzheimer&aposs disease patientAlzheimer&aposs disease therapeuticBehavioral SymptomsBiological AssayBrainBrain regionCell Culture TechniquesCell CycleCell LineCell divisionCell modelChemicalsCoculture TechniquesCognitionCyclin D1CytokinesisDNADisease ProgressionExposure toGene ProteinsGoalsHumanLibrariesMeasuresMediatingMemoryMethodologyModelingMolecularMolecular TargetMusNeuronsPathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstanceProcessSenile PlaquesSignal PathwaySignal TransductionSmall Molecule Chemical LibrarySurrogate MarkersSynapsesSystemabeta oligomerbasehigh throughput screeninginduced pluripotent stem cellinsightnerve stem cellneuron lossnovel therapeuticspreventrelating to nervous systemscreeningsmall moleculesmall molecule inhibitorsmall molecule libraries
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
The death of neurons that control memory and cognition are responsible for the behavioral symptoms of
Alzheimer’s disease (AD). One of the most common pathways for neuronal death in AD is cell cycle re-entry
(CCR), which represents the reactivation of neuronal cell cycle machinery. Usually, differentiated neurons
never attempt to divide, yet up to 5-10% of the neurons in brain regions affected by AD show signs of CCR.
These neurons, which typically have duplicated much of their DNA, fail to undergo cytokinesis. Instead, they
eventually die and may account for as much as 90% of the neuronal loss seen in AD. This process initiates
with exposure to soluble amyloid-β oligomers (AβOs), which are the building blocks of the insoluble amyloid
plaques that accumulate in AD brain. Identifying genes and proteins that mediate AβO-mediated neuronal CCR
and defining relevant signaling networks hold promise for early AD diagnosis and for developing new AD
therapeutics. We have developed a human neural cell model of AβO-mediated neuronal CCR, which utilizes
neural iPS cell lines. We intend to use these iPS lines and derived sublines to develop a high content
screening (HCS) assay to identify chemotypes that inhibit AβO-mediated CCR. We believe, through this assay,
we can identify small molecules that can block AβO-induced neuronal CCR and function as chemical probes to
(1) understand the signaling pathways leading to neuronal death by CCR and (2) serve as parental
chemotypes for drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURVIVAL SIGNALING INHIBITORS AS CANCER DRUGS
-
批准号:6287886
-
项目类别:
-
资助金额:$25.14万
-
财政年份:2001
-
负责人:ELIZABETH SHARLOW
-
依托单位:
SURVIVAL SIGNALING INHIBITORS AS CANCER DRUGS
-
批准号:6420494
-
项目类别:
-
资助金额:$12.61万
-
财政年份:2001
-
负责人:ELIZABETH SHARLOW
-
依托单位:
海外基金